Optimizing in vitro T cell differentiation by using induced pluripotent stem cells with GFP-RUNX1 and mCherry-TCF7 labelling

Abstract

In vitro T-cell differentiation from pluripotent stem cells (PSCs) could potentially provide an unlimited source of T cells for cancer immunotherapy, which, however is still hindered by the inefficient obtaining functionally-matured, terminally-differentiated T cells. Here, we established a fluorescence reporter human induced pluripotent stem cell (iPSC) line termed TCF7^mCherryRUNX1^GFP, in which the endogenous expression of RUNX1 and TCF7 are illustrated by the GFP and mCherry fluorescence, respectively. Utilizing TCF7^mCherryRUNX1^GFP, we defined that the feeder cells incorporating CXCL12-expressing OP9 cells with DL4-expressing OP9 cells at a 1:3 ratio (OP9-C1D3) significantly enhanced efficiency of CD8⁺ T cell differentiation from PSCs. Additionally, we engineered a chimeric antigen receptor (CAR) targeting EGFR into iPSCs. The CAR-T cells differentiated from these iPSCs using OP9-C1D3 feeders demonstrated effective cytotoxicity toward lung cancer cells. We anticipate this platform will help the in vitro HSPC and T cell differentiation optimization, serving the clinical demands of these cells.

References

[1] JuneCH, O’Connor RS, KawalekarOU, GhassemiS, MiloneMC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361-1365.

[2] MenonT, FirthAL, Scripture-AdamsDD, et al. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell. 2015;16:367-372.

[3] NishimuraT, KanekoS, Kawana-TachikawaA, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12:114-126.

[4] ShaferP, KellyLM, HoyosV. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762.

[5] WatanabeK, Nishikawa H. Engineering strategies for broad application of TCR-T-and CAR-T-cell therapies. Int Immunol. 2021;33:551-562.

[6] WeiJ, GuoY, WangY, et al. Clinical development of CAR T cell therapy in China:2020 update. Cell Mol Immunol. 2021;18:792-804.

[7] ZakrzewskiJL, Kochman AA, LuSX, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006;12:1039-1047.

[8] Montel-HagenA, CrooksGM. From pluripotent stem cells to T cells. Exp Hematol. 2019;71:24-31.

[9] SchmittTM, de Pooter RF, GronskiMA, ChoSK, OhashiPS, Zúñiga-PflückerJC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol. 2004;5:410-417.

[10] StrubbeS, TaghonT. Modeling of human T cell development in vitro as a read-out for hematopoietic stem cell multipotency. Biochem Soc Trans. 2021;49:2113-2122.

[11] TakahashiK, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.

[12] TaghonTN, DavidES, Zuniga-PfluckerJC, RothenbergEV. Delayed, asynchronous, and reversible T-lineage specification induced by Notch/Delta signaling. Genes Dev. 2005;19:965-978.

[13] LarbiA, Mitjavila-Garcia MT, FlamantS, et al. Generation of multipotent early lymphoid progenitors from human embryonic stem cells. Stem Cells Dev. 2014;23:2983-2995.

[14] MinagawaA, Yoshikawa T, YasukawaM, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018;23:850-858.e854.

[15] ShuklaS, Langley MA, SinghJ, et al. Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1. Nat Methods. 2017;14:531-538.

[16] Trotman-GrantAC, Mohtashami M, De SousaCJ, et al. DL4-mubeads induce T cell lineage differentiation from stem cells in a stromal cell-free system. Nat Commun. 2021;12:5023.

[17] Montel-HagenA, SeetCS, LiS, et al. Organoid-induced differentiation of conventional T cells from human pluripotent stem cells. Cell Stem Cell. 2019;24:376-389.e378.

[18] Perez Del RioE, SantosF, Rodriguez RodriguezX, et al. CCL21-loaded 3D hydrogels for T cell expansion and differentiation. Biomaterials. 2020;259:120313.

[19] WangZ, McWilliams-Koeppen HP, RezaH, et al. 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29:515-527.e518.

[20] SeetCS, HeC, BethuneMT, et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods. 2017;14:521-530.

[21] ChenMJ, Yokomizo T, ZeiglerBM, DzierzakE, SpeckNA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature. 2009;457:887-891.

[22] HowellED, Yzaguirre AD, GaoP, et al. Efficient hemogenic endothelial cell specification by RUNX1 is dependent on baseline chromatin accessibility of RUNX1-regulated TGFbeta target genes. Genes Dev. 2021;35:1475-1489.

[23] KissaK, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature. 2010;464:112-115.

[24] SwiersG, Baumann C, O’RourkeJ, et al. Early dynamic fate changes in haemogenic endothelium characterized at the single-cell level. Nature Commun. 2013;4:2924.

[25] CalvaneseV, Capellera-Garcia S, MaF, et al. Mapping human haematopoietic stem cells from haemogenic endothelium to birth. Nature. 2022;604:534-540.

[26] ZengY, HeJ, BaiZ, et al. Tracing the first hematopoietic stem cell generation in human embryo by single-cell RNA sequencing. Cell Res. 2019;29:881-894.

[27] JungIY, Narayan V, McDonaldS, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med. 2022;14:eabn7336.

[28] ZhouW, GaoF, Romero-WolfM, JoS, Rothenberg EV. Single-cell deletion analyses show control of pro-T cell developmental speed and pathways by Tcf7, Spi1, Gata3, Bcl11a, Erg, and Bcl11b. Sci Immunol. 2022;7:eabm1920.

[29] QiuY, WangX, YaoY, et al. Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia. Exp Hematol Oncol. 2023;12:18.

[30] AraT, ItoiM, KawabataK, et al. A role of CXC chemokine ligand 12/stromal cell-derived Factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo. J Immunol. 2003;170:4649-4655.

[31] Hernandez-LopezC, Varas A, SacedonR, et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T-cell development. Blood. 2002;99:546-554.

[32] JinL, CaoL, ZhuY, et al. Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6. Sci Bull. 2021;66:803-812.

[33] OkudaT, vanDeursen J, HiebertSW, GrosveldG, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.

[34] LevantiniE, LeeS, RadomskaHS, et al. RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. EMBO J. 2011;30:4059-4070.

[35] CastropJ, van Wichen D, Koomans-BitterM, et al. The human TCF-1 gene encodes a nuclear DNA-binding protein uniquely expressed in normal and neoplastic T-lineage lymphocytes. Blood. 1995;86:3050-3059.

[36] Garcia-PerezL, FamiliF, CordesM, et al. Functional definition of a transcription factor hierarchy regulating T cell lineage commitment. Sci Adv. 2020;6:eaaw7313.

[37] OosterwegelM, van de Wetering M, DooijesD, et al. Cloning of murine TCF-1, a T cell-specific transcription factor interacting with functional motifs in the CD3-epsilon and T cell receptor alpha enhancers. J Exp Med. 1991;173:1133-1142.

[38] WeberBN, ChiAW, ChavezA, et al. A critical role for TCF-1 in T-lineage specification and differentiation. Nature. 2011;476:63-68.

[39] NagasawaT, Kikutani H, KishimotoT. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91:2305-2309.

[40] SugiyamaT, KoharaH, NodaM, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25:977-988.

[41] CalderonL, BoehmT. Synergistic, context-dependent, and hierarchical functions of epithelial components in thymic microenvironments. Cell. 2012;149:159-172.

[42] JanasML, VaranoG, GudmundssonK, NodaM, Nagasawa T, TurnerM. Thymic development beyond β-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J Exp Med. 2010;207:247-261.

[43] PlotkinJ, Prockop SE, LepiqueA, PetrieHT. Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus. J Immunol. 2003;171:4521-4527.

[44] ZhaoF, LuY, LiZ, et al. The CXCR4-CXCL12 axis promotes T cell reconstitution via efficient hematopoietic immigration. J Genet Genomics. 2022;49:1138-1150.

[45] AiutiA, TavianM, CipponiA, et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lymphohematopoietic progenitors. Eur J Immunol. 1999;29:1823-1831.

[46] IshiiT, Nishihara M, MaF, et al. Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells is a phenotypic alteration for committed lymphoid progenitors. J Immunol. 1999;163:3612-3620.

[47] MohtashamiM, ShahDK, KianizadK, Awong G, Zuniga-PfluckerJC. Induction of T-cell development by Delta-like 4-expressing fibroblasts. Int Immunol. 2013;25:601-611.

[48] MinamiH, Nagaharu K, NakamoriY, et al. CXCL12–CXCR4 Axis is required for contact-mediated human B lymphoid and Plasmacytoid dendritic cell differentiation but not T lymphoid generation. The Journal of Immunology. 2017;199:2343-2355.

[49] MichaelsYS, EdgarJM, MajorMC, et al. DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells. Sci Adv. 2022;8:eabn5522.

[50] ZhaoT, ZhangZ-N, RongZ, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212-215.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.